samedan logo

 
 
spacer
home > pmps > spring 2019 > automation: the definition of common sense
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Automation: The Definition of Common Sense

Companies’ continued reliance on manual processes and disparate labelling systems often culminates in pricey product recalls. In 2018, the return of over a million units and 9% of all medical device recall events were due to labelling issues. Organisations are known to spend as much as US $350,000 for every global label change. However, despite opportunities to de-risk the process through automated technologies, many persist with archaic methodologies that leave them vulnerable to human error. This absurdity is as unsustainable as it is avoidable.

As global regulations stiffen and the cost of noncompliance climbs, manufacturers must find a method to end the madness. Those who do will not only remove risk from their business, they will unlock the potential for additional cost savings that could transform the bottom line.

Labelling errors are a recurring reality for medical devices. The scale of the problem has barely shifted since 2012 when, just like now, around 10% of product recalls were label related. However, as label content becomes more complex with the introduction of new regulations, this figure will only increase if companies do not proactively review and strengthen their labelling infrastructure. The telltale signs of suboptimal operations are evident in the most prevalent causes of labelling recalls.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Craig Jones has the responsibility of understanding customer needs and industry challenges to drive solutions to improve efficiency, minimise risk, address regulatory requirements, and provide new approaches to business systems and processes. Craig has 15 years’ experience delivering validated label lifecycle management solutions to life science and healthcare industries, including medical device, pharma, and clinical trial organisations. His experience includes roles as an industry consultant, in IT management, and as a senior manager for global technical support and professional services.
spacer
Craig Jones
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Bormioli Pharma and Pierre Fabre Develop a 100% Recycled PET Packaging for ELUDRIL® Brand Mouthwashes

Bormioli Pharma and Pierre Fabre, a French pharmaceutical and dermo-cosmetic group present in more than 100 countries, are consolidating their partnership started in 2020 through an innovative initiative in eco-design and sustainable development.
More info >>

White Papers

Planning the Execution of a Viral Clearance Study

Eurofins BioPharma Product Testing

Viral clearance studies are a necessary component of any regulatory submission for clinical trials or commercial product approval for all biopharmaceutical products. These studies are performed to evaluate the capability of the purification process to remove or inactivate viruses that could potentially contaminate the starting material. They are complex studies that require substantial financial and personnel resources, as well as specialized scientific expertise to perform. As such, viral clearance studies are often performed at a qualified contract testing laboratory rather than in-house. When multiple parties are involved in this process, clear communication and a comprehensive understanding of the approach and timeline is critical.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement